MENU

RLAY Stock Relay Therapeutics (RLAY, $2.93) price moved above its 50-day Moving Average on May 19, 2025

A.I.dvisor
at Tickeron.com
Loading...
RLAY - Relay Therapeutics
Moving Avg. signal
Bullish Trend
Odds of UP Trend
Tickeron
Moving Avg. signal
Price: $2.93
Daily change: +$0.12 (+4.27%)
Daily volume: 1.3M
Capitalization: $502.3M
Industry: Biotechnology
This price move could indicate a change in the trend, and may be a buy signal for investors. A.I.dvisor found 44 similar cases, and were successful. Based on this data, the odds of success are

RLAY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on May 13, 2025

RLAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 46 cases where RLAY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where RLAY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 142 cases where RLAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RLAY as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RLAY turned negative on May 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

RLAY moved below its 50-day moving average on May 21, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.680) is normal, around the industry mean (16.392). P/E Ratio (0.000) is within average values for comparable stocks, (59.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.199). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (56.818) is also within normal values, averaging (279.777).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RLAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
399 Binney Street
Phone
+1 617 370-8837
Employees
323
Web
https://www.relaytx.com